glp 1 and gip for weight loss GLP-1/GIP Results After 1, 3, 6 Months GLP-1 agonists are often called

Description

This is convenient, but it does raise questions about thoroughness

The 39-year-old, who was diagnosed two years ago and has kidney damage, described Ozempic as "life-changing" because it allows her to maintain a normal diet without extreme restrictions to keep her blood sugar stable

Goal: Type 2 diabetes management (A1C reduction) If you prefer once-weekly injections: Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), or efpeglenatide (Eperzan) If you prefer daily injections: Liraglutide (Victoza) or lixisenatide (Adlyxin) If you prefer oral medication: Semaglutide (Rybelsus) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide (if eligible under shortage provisions) Goal: Weight loss (obesity or overweight with comorbidities) If you want maximum weight loss: Retatrutide (Retara, triple agonist, 24% mean loss) or tirzepatide (Zepbound, dual agonist, 20% to 22% mean loss) If you want proven long-term safety data: Semaglutide (Wegovy, 15% to 17% mean loss, 5+ years post-approval data) If you prefer oral medication: Orforglipron (Orfoglip, 15% mean loss, oral once daily) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide Goal: Both diabetes and weight loss If you have significant obesity (BMI over 35): Tirzepatide (Mounjaro for diabetes indication, Zepbound for obesity indication

Tang, and S

[29] demonstrated that the insulin secretion response to an oral glucose overload was greater to that obtained after intravenous perfusion with the same amount of glucose